Smith & Nephew (LON:SN) plc (NYSE:SNN) , recently announced favorable outcome of a clinical study evaluating its REGENETEN Bioinductive Implant in the treatment of large (3-5cm) and massive (5cm+) rotator cuff tears.
This development highlights the company’s commitment toward strengthening its Global Sports Medicine business segment.
About the Study
The prospective, non-comparative arm study of the REGENETEN implant, conducted across 23 patients suffering from large and massive tears in the United States, highlighted a 96% tendon healing rate at two years. No significant difference was found between the treatments of primary repairs and revision surgery.
This study offers strong evidence in favor of REGENETEN as a suitable treatment option, which can cover the entire range of tears from partial to large and massive ones.
Tendon healing was evaluated by consecutive ultrasound examinations to 24 months and a single post-operative MRI. Tendon thickness was observed to have increased from three months to 12 months before marginally diminishing at 24 months. This was indicative of the functional remodeling of the new tissue. No implant-related adverse events took place as a result of the use of the REGENETEN Bioinductive Implant.
The REGENETEN Bioinductive Implant is currently available in the United States.
Recent Developments
Lately, the company has been conducting crucial research studies that have bolstered its Global Sports Medicine segment.
In October 2019, Smith & Nephew announced favorable results for its NOVOSTITCH Meniscal Repair System demonstrating one-year results of the STITCH Study. The NOVOSTITCH Meniscal Repair System caters to complex meniscal tear patterns not properly served by other repair systems currently available in the market. The STITCH Study is the first prospective clinical trial to assess the proficiency of repairing Horizontal Cleavage Tears - one of the most common meniscal tears that affects nearly one-third of patients with this injury.
Price Performance
In a year's time, shares of Smith & Nephew have gained 19.5% compared with the industry’s 8% growth.
Zacks Rank & Stocks to Consider
Smith & Nephew currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are Haemonetics Corporation (NYSE:HAE) , NuVasive, Inc (NASDAQ:NUVA) and ResMed (NYSE:RMD) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Haemonetics has a projected long-term earnings growth rate of 13.5%.
NuVasive has an expected long-term earnings growth rate of 10.9%.
ResMed has a long-term earnings growth rate to be 12.9%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Haemonetics Corporation (HAE): Free Stock Analysis Report
ResMed Inc. (RMD): Free Stock Analysis Report
NuVasive, Inc. (NUVA): Free Stock Analysis Report
Smith & Nephew SNATS, Inc. (SNN): Free Stock Analysis Report
Original post